近日，多家券商机构对诺诚健华（688428.SH，9969.HK）发布研究报告，浦银国际、招银国际、开源证券、首创证券等均给予“买入”评级。诺诚健华日前披露一季报显示，2025年第一季度总收入同比增长129.9%，达到3.8亿元；净利润达到0.14亿元，当季度实现盈利。收入增长主要归功于核心产品奥布替尼（商品名：宜诺凯 ）的持续放量以及公司与Prolium达成授权许可获得的首付款。奥布替尼当季同比...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.